Long-term efficacy of ibrutinib-venetoclax for first-line treatment in chronic lymphocytic leukaemia
Mené sur 211 patients atteints d'une leucémie lymphoïde chronique (durée médiane : 46 mois), cet essai multicentrique de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement de première ligne combinant ibrutinib et vénétoclax dispensé pendant une durée fixe par rapport à un traitement combinant chlorambucil et obinutuzumab
The results of the primary endpoint of the GLOW study 1 formed the basis for approval of ibrutinib (a BTK inhibitor) and venetoclax (a BCL-2 inhibitor) combination therapy for first-line treatment of chronic lymphocytic leukaemia. This approach is now integrated in clinical practice. However, the analysis of long-term data by Carsten U Niemann and colleagues, 2 after a median observation time of nearly 4 years, can address several key questions that have arisen in the context of this therapy.
The Lancet Oncology 2023